DREAM target reactivation by core transcriptional regulators supports neuroblastoma growth

Area of Science:

• Oncology
• Molecular Biology
• Genetics

Background:

• Chromosome 17q gains are frequent in high-risk neuroblastomas.
• The functional role of these 17q alterations remains largely unknown.
• Understanding the molecular drivers of neuroblastoma is crucial for targeted therapies.

Purpose of the Study:

• To identify key genes and regulatory mechanisms associated with 17q gains in neuroblastoma.
• To elucidate the functional significance of identified alterations in driving tumor proliferation.
• To explore potential therapeutic vulnerabilities arising from these mechanisms.

Main Methods:

• Analysis of genomic alterations in neuroblastoma samples.
• Identification of super-enhancer regions and associated transcription factors.
• Investigation of gene regulatory networks involving MYCN, FOXM1, and DREAM complex.
• In vitro studies assessing the impact of gene inhibition on proliferation.

Main Results:

• A 17q super-enhancer regulated T-box Transcription Factor 2 (TBX2) was identified as a key driver.
• TBX2 was found to be part of a core regulatory circuitry enhancing MYCN/FOXM1 reactivation of DREAM targets.
• This circuitry significantly drives neuroblastoma proliferation.
• Combined inhibition of cyclin-dependent kinase 7 (CDK7) and bromodomain proteins showed synergistic effects.

Conclusions:

• TBX2, regulated by a 17q super-enhancer, is a critical oncogenic driver in high-risk neuroblastoma.
• The TBX2-mediated enhancement of MYCN/FOXM1-DREAM target reactivation drives tumor cell proliferation.
• Targeting CDK7 and bromodomain proteins offers a potential synergistic therapeutic strategy for neuroblastoma with 17q gains.